Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Effect of the incretin hormones on the endocrine pancreas in end-stage renal disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hydroxylated Long-Chain Acylcarnitines are Biomarkers of Mitochondrial Myopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Quantitative Differences in TGF-β Family Members Measured in Small Antral Follicle Fluids From Women With or Without PCO

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Over- and Under-Treatment of Hypothyroidism Is Associated with Excess Mortality: A Register-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Bente L Langdahl
  • Christence Stubbe Teglbjærg
  • Pei-Ran Ho
  • Roland Chapurlat
  • Edward Czerwinski
  • David L Kendler
  • Jean-Yves Reginster
  • Alan Kivitz
  • E Michael Lewiecki
  • Paul D Miller
  • Michael A Bolognese
  • Michael R McClung
  • Henry G Bone
  • Östen Ljunggren
  • Bo Abrahamsen
  • Ugis Gruntmanis
  • Yu-Ching Yang
  • Rachel B Wagman
  • Faisal Mirza
  • Suresh Siddhanti
  • Eric Orwoll
View graph of relations

CONTEXT: One in 4 men in the United States aged >50 years will have an osteoporosis-related fracture. Fewer data are available on osteoporosis treatment in men than in women.

OBJECTIVE: The purpose of this study was to evaluate denosumab therapy in men with low bone mineral density (BMD).

DESIGN: This was a phase 3 study with 2 treatment periods: a previously reported 12-month double-blind, placebo-controlled phase and a 12-month open-label phase.

SETTING: This was a multicenter study conducted in North America and Europe.

PARTICIPANTS: A total of 228 men entered the open-label phase and 219 completed the study.

INTERVENTION: Men from the original denosumab (long-term) and placebo (crossover) groups received 60 mg of denosumab sc every 6 months.

MAIN OUTCOME MEASURES: BMD, serum collagen type I C-telopeptide, and safety were measured.

RESULTS: During the open-label phase, continued BMD increases occurred with long-term denosumab treatment (2.2% lumbar spine, 0.9% total hip, 1.3% femoral neck, 1.3% trochanter, and 0.2% 1/3 radius), resulting in cumulative 24-month gains from baseline of 8.0%, 3.4%, 3.4%, 4.6%, and 0.7%, respectively (all P < .01). The crossover group showed BMD gains after 12 months of denosumab treatment similar to those of the long-term denosumab group during the first treatment year. Significant reductions in serum collagen type I C-teleopeptide were observed after denosumab administration. Adverse event rates were similar between groups, and no new safety signals were identified.

CONCLUSIONS: In men with low BMD, denosumab treatment for a second year continued to increase BMD, maintained reductions in bone resorption, and was well tolerated. BMD increased in men initiating denosumab during the second year. These effects were similar to those previously seen in postmenopausal women with osteoporosis and in men with prostate cancer receiving androgen deprivation therapy.

Original languageEnglish
JournalThe Journal of clinical endocrinology and metabolism
Volume100
Issue number4
Pages (from-to)1335-42
Number of pages8
ISSN0021-972X
DOIs
Publication statusPublished - Apr 2015

    Research areas

  • Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, Biomarkers, Bone Density, Bone Density Conservation Agents, Denosumab, Femur Neck, Fractures, Bone, Humans, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Radius, Treatment Outcome

ID: 45983594